{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"27","upperLimit":"1605","value":"180"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"9"}],"units":"Participants"}],"description":"The Kaplan-Meier method will be used to estimate overall survival.","dispersionType":"Full Range","groups":[{"description":"Patients receive saracatinib PO or by PEG tube QD on days 1-56. Courses repeat every 8 weeks in the absence of disease progression or unacceptable toxicity.","id":"OG000","title":"Treatment (Enzyme Inhibitor Therapy)"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"Up to 12 weeks","title":"Overall Survival","type":"SECONDARY","unitOfMeasure":"Days"}